Rabies Vaccine Market By Product Type (Chick embryo cells rabies vaccine, Vero cell rabies vaccine, Human diploid cell vaccine, Others), By Prophylaxis Type (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Application (Human, Animal), By End User

Rabies Vaccine Market By Product Type (Chick embryo cells rabies vaccine, Vero cell rabies vaccine, Human diploid cell vaccine, Others), By Prophylaxis Type (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Application (Human, Animal), By End User (Hospitals, Veterinary clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

The Rabies Vaccine Market was valued at $1,207.03 million in 2022 and is estimated to reach $1,903.17 million by 2032, exhibiting a CAGR of 4.7% from 2023 to 2032.

Rabies is a virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. It is an illness that a person gets from an infection with the RABV virus. It causes symptoms such as seizures, hallucinations, and paralysis. The rabies vaccine is a vaccine used to prevent rabies. Moreover, there are several rabies vaccines available that are both safe and effective. They are used to prevent rabies before, and, for a period, after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.

The rabies vaccine market growth is driven by increase in prevalence of rabies, rise in initiatives taken by government, and surge in awareness regarding rabies vaccine. The incidence of rabies in animals and humans is a significant driver for the rabies vaccine market. In regions where rabies is endemic, there is a higher demand for rabies vaccines to prevent the spread of the disease. For instance, according to World Health Organization, (WHO), in September 2023, it was reported that, rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. It causes tens of thousands of deaths every year, mainly in Asia and Africa, 40% of whom are children under 15 years of age. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humans. Rabies can be prevented through vaccination of dogs and prevention of dog bites.

In addition, government-led rabies control and prevention programs often involve mass vaccination campaigns for animals and sometimes even free or subsidized vaccinations for humans who have been exposed to the virus. Government funding and support boost the market for rabies vaccines. Moreover, increased awareness about the risks of rabies and the importance of vaccination drive demand for rabies vaccines. Public health campaigns and educational efforts contribute to this awareness.

On the other hand, rabies vaccination, particularly post-exposure prophylaxis (PEP), is expensive. The high cost of treatment acts as a restraint, especially in regions with limited healthcare resources or where people are not able to afford the vaccine.

The rabies vaccine market is segmented into product type, prophylaxis type, application, end user, and region. By product type, the market is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. By prophylaxis type, the market is categorized into pre-exposure prophylaxis and post exposure prophylaxis. By application, the market is segmented into human and animal. By end user, the market is divided into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global rabies vaccine market are Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2022 to 2032 to identify the prevailing rabies vaccine market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product Type

Chick embryo cells rabies vaccine
Vero cell rabies vaccine
Human diploid cell vaccine
Others

By Prophylaxis Type

Pre-exposure prophylaxis
Post-exposure prophylaxis

By Application

Human
Animal

By End User

Hospitals
Veterinary clinics
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Serum Institute of India Pvt. Ltd.
Sanofi
Boehringer Ingelheim International GmbH
Elanco Animal Health Incorporated.
Virbac SA
Novartis AG
Cadila Pharmaceuticals Ltd
Bharat Biotech International Limited
Zoetis Inc.
Merck & Co., Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.